Contineum Therapeutics, Inc.

CTNM

Financials

10-QQ2 ended 06/30/2607/30/26 10-QQ1 ended 03/31/2605/05/26 10-KFY 202503/05/26 10-QQ3 ended 09/30/2510/30/25 10-QQ2 ended 06/30/2508/05/25

Disclosures

8-KCurrent report09/14/26 8-KCurrent report07/30/26 8-KCurrent report07/13/26 8-KCurrent report06/26/26 8-KCurrent report05/05/26

Prospectuses and Registrations

424B5Prospectus supplement03/05/26 S-8Registration of securities for employees03/05/26 424B5Prospectus supplement12/12/25 424B5Prospectus supplement12/11/25 S-3Shelf registration05/14/25

Proxies

DEF 14ADefinitive proxy04/30/26 DEFA14AAdditional proxy materials04/30/26 DEF 14ADefinitive proxy04/29/25 DEFA14AAdditional proxy materials04/29/25

Ownership

SC 13GBeneficial ownership10/28/26 SC 13G/ABeneficial ownership (amended)10/28/26 SC 13GBeneficial ownership10/22/26 144Proposed sale of securities10/01/26 144Proposed sale of securities09/08/26

Other

ARSAnnual report to shareholders04/30/26 EFFECTRequest for effectiveness05/23/25 CORRESPCorrespondence with the SEC05/21/25 UPLOADLetter from the SEC05/20/25 ARSAnnual report to shareholders04/29/25